Total Payments
$123,959
2024 Payments
$22,677
Companies
29
Transactions
475
Medicare Patients
5,733
Medicare Billing
$993,621
Payment Breakdown by Category
Other$94,999 (76.6%)
Consulting$11,953 (9.6%)
Food & Beverage$11,264 (9.1%)
Travel$5,436 (4.4%)
Education$308.04 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $93,499 | 63 | 75.4% |
| Consulting Fee | $11,953 | 6 | 9.6% |
| Food and Beverage | $11,264 | 382 | 9.1% |
| Travel and Lodging | $5,436 | 16 | 4.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,500 | 1 | 1.2% |
| Education | $308.04 | 7 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $34,902 | 80 | $0 (2020) |
| PFIZER INC. | $27,146 | 42 | $0 (2024) |
| Melinta Therapeutics, LLC | $21,654 | 39 | $0 (2024) |
| Cumberland Pharmaceuticals, Inc. | $14,738 | 50 | $0 (2024) |
| ABBVIE INC. | $8,133 | 25 | $0 (2024) |
| Mylan Inc. | $7,803 | 1 | $0 (2018) |
| Merck Sharp & Dohme LLC | $5,856 | 41 | $0 (2024) |
| ViiV Healthcare Company | $1,379 | 93 | $0 (2024) |
| Gilead Sciences, Inc. | $777.32 | 39 | $0 (2024) |
| Astellas Pharma US Inc | $326.81 | 13 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22,677 | 113 | Cumberland Pharmaceuticals, Inc. ($9,881) |
| 2023 | $8,380 | 54 | Melinta Therapeutics, LLC ($4,496) |
| 2022 | $17,032 | 60 | Melinta Therapeutics, LLC ($12,739) |
| 2021 | $2,527 | 53 | Cumberland Pharmaceuticals, Inc. ($1,628) |
| 2020 | $3,301 | 37 | Allergan, Inc. ($2,815) |
| 2019 | $15,665 | 51 | Allergan Inc. ($9,937) |
| 2018 | $26,632 | 46 | PFIZER INC. ($12,019) |
| 2017 | $27,745 | 61 | Allergan Inc. ($15,563) |
All Payment Transactions
475 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $8.50 | General |
| Category: HIV | ||||||
| 12/13/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $31.82 | General |
| Category: HIV | ||||||
| 12/11/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: HIV | ||||||
| 12/11/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: VACCINES | ||||||
| 12/03/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ, DALVANCE | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/21/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ, DALVANCE | Food and Beverage | In-kind items and services | $16.02 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/20/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $8.78 | General |
| Category: HIV | ||||||
| 11/19/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,500.00 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 11/19/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Travel and Lodging | Cash or cash equivalent | $577.75 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 11/17/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $122.93 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 11/15/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: HIV | ||||||
| 11/15/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: Infections and Infectious Diseases | ||||||
| 11/12/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: HIV | ||||||
| 10/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.08 | General |
| 10/29/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $12.79 | General |
| Category: HIV | ||||||
| 10/17/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $30.11 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/16/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ, DALVANCE | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/03/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: HIV | ||||||
| 10/02/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Orbactiv, Rezzayo | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: ANTIBIOTICS | ||||||
| 09/30/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $15.91 | General |
| Category: VACCINE | ||||||
| 09/25/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $6.81 | General |
| Category: HIV | ||||||
| 09/25/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $2.58 | General |
| Category: HIV | ||||||
| 09/24/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 09/24/2024 | PFIZER INC. | PREVNAR 20 (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: VACCINES | ||||||
| 09/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.51 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 1,380 | 2,446 | $510,096 | $232,504 |
| 2022 | 8 | 1,426 | 3,109 | $395,674 | $269,877 |
| 2021 | 6 | 1,444 | 2,641 | $346,565 | $239,043 |
| 2020 | 6 | 1,483 | 2,850 | $367,055 | $252,198 |
Total Patients
5,733
Total Services
11,046
Medicare Billing
$993,621
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 648 | 1,641 | $248,420 | $121,336 | 48.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 298 | 302 | $115,566 | $48,639 | 42.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 149 | 184 | $43,653 | $20,233 | 46.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 139 | 142 | $31,772 | $17,310 | 54.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 63 | 90 | $30,168 | $10,562 | 35.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 28 | 28 | $15,100 | $5,859 | 38.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 19 | 21 | $12,025 | $4,229 | 35.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 14 | 15 | $6,569 | $2,536 | 38.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 23 | $6,823 | $1,801 | 26.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 734 | 2,354 | $235,400 | $158,303 | 67.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 300 | 312 | $84,240 | $58,417 | 69.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 163 | 168 | $31,270 | $21,743 | 69.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 126 | 157 | $21,195 | $15,166 | 71.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 49 | 64 | $10,415 | $7,386 | 70.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 20 | 20 | $5,840 | $4,132 | 70.8% |
| 99285 | Emergency department visit for life threatening or functioning severity | Facility | 2022 | 17 | 17 | $5,100 | $2,948 | 57.8% |
| 99284 | Emergency department visit for problem of high severity | Facility | 2022 | 17 | 17 | $2,214 | $1,781 | 80.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 733 | 1,853 | $185,300 | $124,835 | 67.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 306 | 310 | $83,700 | $58,307 | 69.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 165 | 170 | $31,365 | $21,867 | 69.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 155 | 196 | $26,460 | $19,002 | 71.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 56 | 83 | $11,620 | $9,018 | 77.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 29 | 29 | $8,120 | $6,013 | 74.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 809 | 2,069 | $206,900 | $139,251 | 67.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 346 | 364 | $98,280 | $69,122 | 70.3% |
About Dr. Alan Bulbin, M.D
Dr. Alan Bulbin, M.D is a Infectious Disease healthcare provider based in Greenvale, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053360628.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan Bulbin, M.D has received a total of $123,959 in payments from pharmaceutical and medical device companies, with $22,677 received in 2024. These payments were reported across 475 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($93,499).
As a Medicare-enrolled provider, Bulbin has provided services to 5,733 Medicare beneficiaries, totaling 11,046 services with total Medicare billing of $993,621. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Greenvale, NY
- Active Since 05/09/2006
- Last Updated 03/21/2023
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1053360628
Products in Payments
- DALVANCE (Drug) $36,705
- PREVNAR - 13 (Biological) $21,952
- Vabomere (Drug) $14,830
- VIBATIV (Drug) $14,220
- Kimyrsa (Drug) $6,803
- AVYCAZ (Drug) $5,277
- ZERBAXA (Drug) $5,247
- PREVNAR 20 (Biological) $3,245
- XALKORI (Drug) $1,221
- DOVATO (Drug) $740.52
- TEFLARO (Drug) $602.72
- CABENUVA (Biological) $348.86
- CALDOLOR (Drug) $289.54
- XERAVA (Drug) $268.07
- Vibativ (Drug) $179.38
- Fetroja (Drug) $169.52
- DIFICID (Drug) $166.54
- APRETUDE (Biological) $148.15
- BRIDION (Drug) $124.69
- CRESEMBA (Drug) $123.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Greenvale
Vitaliy Krol, Do, DO
Infectious Disease — Payments: $2,759
Infectious Disease $2,759
Farah Shams, Md, MD
Infectious Disease — Payments: $1,992
Infectious Disease $1,992
Dr. David Brieff, M.d, M.D
Infectious Disease — Payments: $220.99
Infectious Disease $220.99
Dr. Dava Klirsfeld, Md, MD
Infectious Disease — Payments: $180.42
Infectious Disease $180.42
Dr. Hermes Lopez, Md, MD
Infectious Disease — Payments: $110.09
Infectious Disease $110.09
Nathalie Schulhof, Md, MD
Infectious Disease
Infectious Disease